-
The durability of vaccine-induced protection: an overview Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-03-15 Vipin M. Vashishtha, Puneet Kumar
Current vaccines vary widely in both their efficacy against infection and disease, and the durability of the efficacy. Some vaccines provide practically lifelong protection with a single dose, whil...
-
Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-03-12 Xuanxuan Zhang, Jialu Zhang, Si Chen, Qian He, Yu Bai, Jianyang Liu, Zhongfang Wang, Zhenglun Liang, Ling Chen, Qunying Mao, Miao Xu
Following the coronavirus disease pandemic, respiratory mucosal vaccines that elicit both mucosal and systemic immune responses have garnered increasing attention. However, human physiological char...
-
Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-03-05 Mitsuhiro Nagano, Kazumasa Kamei, Hiroyuki Matsuda, Chihiro Takahashi, Jingyan Yang, Koji Wada, Naohiro Yonemoto
The aim of this study was to evaluate the public health and economic impact of the COVID-19 booster vaccination with BNT162b2 in Japan during an Omicron-dominant period from early 2022.A combined c...
-
Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-02-28 James J Bull, Scott L Nuismer, Christopher H Remien, Megan E Griffiths, Rustom Antia
Transmissible vaccines offer a novel approach to suppressing viruses in wildlife populations, with possible applications against viruses that infect humans as zoonoses – Lassa, Ebola, rabies. To en...
-
Assessment of the comprehensiveness of paediatric national immunisation programmes in Europe: expert validation and future perspectives Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-03-01 Ugne Sabale, Janice Murtagh, James Cochrane, Danielle Riley, Richard Perry, Louise Heron, Paolo Bonanni, Jose Navarro Alonso, Juhani Eskola, Valerie Laigle
The breadth of protection of National Immunisation Programmes (NIPs) across Europe varies, however, this has not been assessed within published literature. Therefore, a framework was developed to a...
-
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-02-26 Alberto San Francisco Ramos, Carolina Liu Sanchez, Tatiana Bovill Rose, David Smith, Natasha Thorn, Eva Galiza, Thahmena Miah, Jennifer Pearce, Cecilia Hultin, Catherine Cosgrove, Yingfen Hsia, Paul T. Heath
Different COVID-19 vaccines are being utilized as boosters. This systematic review and meta-analysis aims to evaluate the reactogenicity of COVID-19 vaccines given as booster doses, according to va...
-
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-03-01 Daisuke Kurai, Akiko Mizukami, Victor Preckler, Frederik Verelst, Daniel Molnar, Taizo Matsuki, Yufan Ho, Ataru Igarashi
Respiratory syncytial virus (RSV), a common respiratory pathogen, can lead to severe symptoms, especially in older adults (OA). A recently developed RSV prefusion F protein (RSVPreF3 OA) vaccine co...
-
Cost-effectiveness of nonavalent HPV vaccination in the Netherlands Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-03-01 Cody Palmer, Christiaan Dolk, Ugne Sabale, Wei Wang, Kunal Saxena
A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.We compared the public health and economic benefits of 2vHPV- and...
-
The mRNA vaccine, a swift warhead against a moving infectious disease target Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-03-01 Sheema Mir, Mohammad Mir
The rapid development of mRNA vaccines against SARS-CoV-2 has revolutionized vaccinology, offering hope for swift responses to emerging infectious diseases. Initially met with skepticism, mRNA vacc...
-
Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-02-27 Viravarn Luvira, Punnee Pitisuttithum
Inactivated vaccines were delivered to low- and middle-income countries during the early pandemics of COVID-19. Currently, more than 10 inactivated COVID-19 vaccines have been developed. Most inact...
-
Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-02-19 Xiang Guo, Juan Li, Jing Qiu, Rui Zhang, Jia Ren, Zhuoying Huang, Zhi Li, Xiufang Liang, Fang Lan, Juan Chen, Fang Huang, Xiaodong Sun
Pneumococcal vaccines are effective in preventing pneumococcal diseases in adults. The evaluation of the antibodies persistence to the 23-valent pneumococcal polysaccharide vaccine (PPV23) could pr...
-
Combatting infectious diarrhea: innovations in treatment and vaccination strategies Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-02-19 Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra, Sathvika Kamaraj, Nikita Sharma, Swati Punetha, Anand Sairam, Dixa Vaghela, Narges Dargahi, Vasso Apostolopoulos
The escalating prevalence of infectious diseases is an important cause of concern in society. Particularly in several developing countries, infectious diarrhea poses a major problem, with a high fa...
-
Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-02-16 Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen
Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low...
-
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-02-08 Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Mayumi Terada, Shingo Masuda, Ryosuke Osawa, Naoto Hosokawa, Kei Nakashima, Hiroshi Kamura, Haruki Imura, Hiroki Inoue, Suguru Matsuzaka, Yukihiro Sugimoto, Osamu Kuwamitsu, Iori Motohashi, Toru Morikawa, Rentaro Oda, Yuiko Hoshina, Takashi Matono, Osamu Teshigahara, Eiichiro Sando, Sadaharu Asami, Satoshi Kudo, Noboru Akizuki, Yoshikazu Muto
This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan.We conducted ...
-
Neoadjuvant personalized cancer vaccines: the final frontier? Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-01-10 Guilhem Richard, Nicole Ruggiero, Gary D. Steinberg, William D. Martin, Anne S. De Groot
Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens...
-
Multiple antigen presenting system (MAPS): state of the art and potential applications Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-01-08 Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O. Willer
Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly re...
-
Modeling undetected poliovirus circulation following the 2022 outbreak in the United States Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-01-04 Dominika A. Kalkowska, Kamran Badizadegan, Janell A. Routh, Cara C. Burns, Eli S. Rosenberg, I. Ravi Brenner, Jane R. Zucker, Marisa Langdon-Embry, Kimberly M. Thompson
New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for whi...
-
Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses Expert Rev. Vaccines (IF 6.2) Pub Date : 2024-01-03 Syamala R. Thimmiraju, Jason T. Kimata, Jeroen Pollet
Pseudoviruses are recombinant, replication-incompetent, viral particles designed to mimic the surface characteristics of native enveloped viruses. They are a safer, and cost-effective research alte...
-
Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-27 Richard Thomson-Luque, Thomas C Stabler, Kristin Fürle, Joana C Silva, Claudia Daubenberger
Malaria represents a public health challenge in tropical and subtropical regions, and currently deployed control strategies are likely insufficient to drive elimination of malaria. Development and ...
-
Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-22 Juntao Yin, Liang Zhang, Chaoyang Wang, Changjiang Qin, Mingsan Miao
This review aimed to systematically evaluate the immunogenicity and safety of the candidate Ebola virus vaccine (EVV).We searched five databases for randomized controlled trials (RCTs) evaluating t...
-
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-20 Timothy J Chapman, Liset Olarte, Ghassan Dbaibo, Avril Melissa Houston, Gretchen Tamms, Robert Lupinacci, Kristen Feemster, Ulrike K Buchwald, Natalie Banniettis
Streptococcus pneumoniae is a causative agent of pneumonia and acute otitis media (AOM), as well as invasive diseases such as meningitis and bacteremia. PCV15 (V114) is a new 15-valent pneumococcal...
-
A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-19 Myron J. Levin, Victoria Divino, Maarten J. Postma, Stephen I. Pelton, Zifan Zhou, Mitch DeKoven, Joaquin Mould-Quevedo
Clinical evidence supports use of enhanced influenza vaccines in older adults. Few economic outcome studies have compared adjuvanted trivalent inactivated (aIIV3) and standard egg-derived quadrival...
-
The use of electroporation to deliver DNA-based vaccines Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-18 Denis N Kisakov, Igor M. Belyakov, Lubov A Kisakova, Vladimir A Yakovlev, Elena V Tigeeva, Larisa I Karpenko
Nucleic acids represent a promising platform for creating vaccines. One disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an effective way to increase the ...
-
Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-15 Laura Colombo, Sanjay Hadigal, Jos Nauta, Alona Kondratenko, Jutta Rogoll, Serge van de Witte
This paper summarizes the safety and immunogenicity data of Influvac Tetra across all age groups starting from 6 months of age, obtained during its clinical development program.The article covers t...
-
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-14 Elizabeth Adrianne Hammershaimb, Andrea A. Berry
Published in Expert Review of Vaccines (Vol. 23, No. 1, 2024)
-
Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-14 Josiah Ryman, Jeffrey R. Sachs, Ka Lai Yee, Natalie Banniettis, Jessica Weaver, Thomas Weiss
Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent PCV (PCV20), have been assessed by comparing their immune responses across serotypes shared ...
-
Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-14 Stephen I. Pelton, Joaquin F. Mould-Quevedo, Van Hung Nguyen
Cell-based quadrivalent influenza vaccines (QIVc) can increase effectiveness against seasonal influenza by avoiding mismatch from egg adaption of vaccine viruses. This study evaluates the populatio...
-
Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system data Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-14 Yiming Li, Sori K Lundin, Jianfu Li, Wei Tao, Yifang Dang, Yong Chen, Cui Tao
The rapid development of COVID-19 vaccines has provided crucial tools for pandemic control, but the occurrence of vaccine-related adverse events (AEs) underscores the need for comprehensive monitor...
-
Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-14 Jiamin Qiu, Shiwen Zhang, Yonghui Feng, Xin Su, Jun Cai, Shiyun Chen, Jiazi Liu, Shiqi Huang, Haokun Huang, Sui Zhu, Huiyan Wen, Jiaxin Li, Haoyu Yan, Zhiquan Diao, Xiaofeng Liang, Fangfang Zeng
There is a lack of synthesis of literature to determine hepatitis B vaccine (HepB) strategies for hepatitis B virus (HBV) supported by quality evidence. We aimed to explore the efficacy and safety ...
-
Influenza B virus neuraminidase: a potential target for next-generation vaccines? Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-14 Thi Hoai Thu Do, Adam K. Wheatley, Stephen J. Kent, Marios Koutsakos
Influenza B viruses (IBV) cause a significant health and economic burden annually. Due to lower antigenic drift rate, less extensive antigenic diversity, and lack of animal reservoirs, the developm...
-
Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-12 Chiara de Waure, Barbara C. Gärtner, Pier Luigi Lopalco, Joan Puig-Barbera, Jonathan S. Nguyen-Van-Tam
Influenza causes significant morbidity and mortality, but influenza vaccine uptake remains below most countries’ targets. Vaccine policy recommendations vary, as do procedures for reviewing and app...
-
Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-12 Karan Thakkar, Julia Spinardi, Moe H. Kyaw, Jingyan Yang, Carlos Fernando Mendoza, Egemen Ozbilgili, Bulent Taysi, Josie Dodd, Ben Yarnoff, Helen M Oh
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 has been a dynamically changing virus, requiring the development of adapted vaccines. This study estimated the potentia...
-
Tackling vaccine inequity in 2023: have we made progress? Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-11 Els Torreele
Published in Expert Review of Vaccines (Vol. 23, No. 1, 2024)
-
Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons in Italy Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-11 Francesco Lapi, Ettore Marconi, Elettra Fallani, Marco Salvatore, Maura Cambiaggi, Alessandro Rossi, Claudio Cricelli
Delays in influenza vaccine delivery and administration can hinder vaccine coverage and protection. This study examines the differentials in distributing and administering adjuvanted trivalent (aTI...
-
Progress toward the development of Lassa vaccines Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-11 Hinh Ly
Published in Expert Review of Vaccines (Vol. 23, No. 1, 2024)
-
DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-06 Florence Boisnard, Christine Manson, Laurence Serradell, Denis Macina
Hexaxim® is fully liquid, hexavalent, combination vaccine that provides immunization against diphtheria, tetanus, pertussis (whooping cough), polio, hepatitis B, and invasive diseases caused by Hae...
-
A retrospective cohort study: vaccination status and safety analysis of SARS-CoV-2 vaccine in patients with Wilson’s disease Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-12-01 Hui Han, Dan Zhao, Xinru Fang, Wenming Yang, Mengli Wang, Qianzhuo Liu, Luyao Wang, Zhihui Ji, Juan Zhang, Zhifeng Hou, Lei Hua, Yu Wang, Limin Wu
Wilson’s disease (WD) is a rare hepatic and neurological disorder, which can dramatically worsen by traumatic injuries, surgeries, and infections. No studies have reported safety data of severe acu...
-
Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-27 Rui Lin, Hui Jin, Xin Fu
Despite their use, differences in human papillomavirus (HPV) vaccine efficacies remain uncertain. This study assesses efficacy differences among bivalent, quadrivalent, and nine-valent HPV (2vHPV, ...
-
Effectiveness of pneumococcal vaccination on hospitalization and death in the adult and older adult diabetic population: a systematic review Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-27 Marco Del Riccio, Sara Boccalini, Claudia Cosma, Gabriele Vaccaro, Benedetta Bonito, Beatrice Zanella, Cristina Salvati, Duccio Giorgetti, Lisa Rigon, Massimiliano Alberto Biamonte, Matteo Monami, Paolo Bonanni, Angela Bechini
Diabetic patients are at a higher risk of getting pneumococcal disease and are therefore recommended to get vaccinated. The aim of our systematic review is the retrieval and analysis of all availab...
-
Have mRNA vaccines sentenced DNA vaccines to death? Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-17 Alberto Cagigi, Bruno Douradinha
After receiving emergency approval during the COVID-19 pandemic, mRNA vaccines have taken center stage in the quest to enhance future vaccination strategies for both infectious diseases and cancer....
-
Vaccination against pertussis in Latin American preterm and low-birth weight infants: experts opinion position for a neglected childhood age group Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-13 María L Avila-Agüero, Sebastián Ospina-Henao, Cristina Mariño, Mirella Vázquez-Rivera, Juan Pablo Torres, Dora Estripeaut, Rolando Ulloa-Gutierrez, Angela Gentile
Pertussis remains as one of the oldest leading vaccine-preventable diseases of childhood, despite many decades of primary vaccine doses’ and boosters’ implementation. Although the epidemiology is w...
-
Vaccine development for pathogenic fungi: current status and future directions Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-13 Jéssica L. Chechi, Felipe A. C. da Costa, Julia M. Figueiredo, Cássia M. de Souza, Alessandro F. Valdez, Daniel Zamith-Miranda, Aline C. Camara, Carlos P. Taborda, Joshua D. Nosanchuk
Fungal infections are caused by a broad range of pathogenic fungi that are found worldwide with different geographic distributions, incidences, and mortality rates. Considering that there are relat...
-
Glycoconjugate vaccines against antimicrobial resistant pathogens Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-08 Charlotte Sorieul, Marta Dolce, Maria Rosaria Romano, Jeroen Codée, Roberto Adamo
Antimicrobial resistance (AMR) is responsible for the death of millions worldwide and stands as a major threat to our healthcare systems, which are heavily reliant on antibiotics to fight bacterial...
-
Risks of low vaccination coverage and strategies to prevent the resurgence of vaccine-preventable diseases in infants in the COVID-19 pandemic scenario: recommendations for Latin America and the Caribbean by the group of experts on infant immunization for Latin America Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-08 Maria L. Avila Agüero, Jose Brea Del Castillo, Luiza Helena Falleiros-Arlant, Eitan Berezín, Jose Cassio de Moraes, Carlos Torres-Martínez, Eduardo L. Lopez, María E. Castillo, Almudena Laris-Gonzalez, Fortino Solorzano, Angela Gentile, Juan Pablo Torres Torretti, Eduardo López-Medina
The WHO 2030 Immunization Agenda (IA-2030) harmonizes immunization activity plans at community, national, regional and global levels. Additionally, medical societies play an important role. The Lat...
-
Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-10 Ruyun Gao, Cuiling Zheng, Mengwei Yang, Liyuan Dai, Chen Chen, Jiarui Yao, Zhishang Zhang, Le Tang, Yuankai Shi, Xiaohong Han
Research on immunogenicity after 3rd SARS-CoV-2 vaccine in elder hepatocellular carcinoma (HCC) was limited. This study aimed to investigate the efficacy and influencing factors of inactivated SARS...
-
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-08 Yingping Chen, Xinpei Zhang, Lihui Gong, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Yuting Liao, Lingfeng Yuan, Gang Chen, Huakun Lv
Because SARS-CoV-2 mutations and immunity wane over time, a third dose of heterologous COVID-19 vaccine is proposed for individuals primed with inactivated COVID-19 vaccine.We conducted a single-ce...
-
Public health impact and return on investment of the pediatric immunization program in Poland Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-09 Claire E. Mellott, Rafal Jaworski, Justin Carrico, Sandra E. Talbird, Iwona Dobrowolska, Dominik Golicki, Goran Bencina, Micah Clinkscales, Eugenia Karamousouli, Amanda L Eiden, Ugne Sabale
This study aims to evaluate the epidemiological impact and return on investment of the pediatric immunization program (PIP) in Poland from the healthcare-sector and societal perspectives.A health-e...
-
PreHevbrio: the first approved 3-antigen hepatitis B vaccine Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-06 Timo Vesikari, Joanne M Langley, Vlad Popovic, Francisco Diaz-Mitoma
Hepatitis B remains a major cause of death and morbidity worldwide. Universal childhood immunization programs have been very successful, but many adults remain unprotected or are not optimally prot...
-
Vaccine approaches for antigen capture by liposomes Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-06 Shiqi Zhou, Yuan Luo, Jonathan F. Lovell
Liposomes have been used as carriers for vaccine adjuvants and antigens due to their inherent biocompatibility and versatility as delivery vehicles. Two vial admixture of protein antigens with lipo...
-
Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-11-02 Sophie Marbaix, Annick Mignon, Audrey Taelman, Ahuva Averin, Mark Atwood, Jeffrey Vietri
The Belgian Superior Health Council (SHC) preferentially recommended the 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged ≥65 years, immunocompromised patients, and patients aged ≥5...
-
Immune response and safety of inactivated SARS-CoV-2 vaccines during pregnancy: a real-world observational study Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-27 Yajie Gong, Xi Zhang, Xue Han, Baolan Chen, Yingxia Xu, Jitian Huang, Wenhan Yang, Xi Fu, Qiancui Wang, Zhongjun Li, Chunfeng Wu, Tianran Shen, Yuting Fan, Yingshi Dai, Yaping Qiao, Gang Zeng, Jikai Zhang, Qingsong Chen
As pregnant women are excluded from clinical trials of inactivated SARS-CoV-2 vaccines, it is important to assess the immune response in women receiving the vaccination while unknowingly pregnant.I...
-
Challenges in vaccine transport: can we deliver without the cold chain? Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-27 Irnela Bajrovic, Maria A. Croyle
Published in Expert Review of Vaccines (Vol. 22, No. 1, 2023)
-
Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-27 Felicitas Kühne, Katharina Achtert, Franziska Püschner, Dominika Urbanski-Rini, Juliane Schiller, Ernestine Mahar, Josephine Friedrich, Mark Atwood, Ralf Sprenger, Jeffrey Vietri, Christof von Eiff, Christian Theilacker
Despite national recommendations for use of pneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) remain high in Germany. New pneumococcal conju...
-
Microarray patches: scratching the surface of vaccine delivery Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-27 Jovin J. Y. Choo, Christopher L. D. McMillan, Paul R. Young, David A. Muller
Microneedles are emerging as a promising technology for vaccine delivery, with numerous advantages over traditional needle and syringe methods. Preclinical studies have demonstrated the effectivene...
-
No observable influence of COVID-19 inactivated vaccines on pregnancy and birth outcomes in the first trimester of gestation Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-19 Ting Du, Qiuxia Qu, Yawen Zhang, Qin Huang
While studies have demonstrated that certain COVID-19 vaccines administered during pregnancy did not affect neonatal or maternal outcomes significantly, the safety of inactivated SARS-CoV-2 vaccine...
-
The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-19 Peter D Skidmore, Rocio Canals, Maheshi N Ramasamy
Published in Expert Review of Vaccines (Vol. 22, No. 1, 2023)
-
An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-19 Shahrul Mt-Isa, Justin R. Chumbley, Emma L. Crawford, Natalie Banniettis, Ulrike K. Buchwald, Jessica Weaver, Thomas Weiss
Immunogenicity between 15-valent V114 (PCV15) and 20-valent PCV20 pneumococcal conjugate vaccines in healthy infants is compared in an indirect treatment comparison and matching-adjusted indirect c...
-
Mucosal vaccination: onward and upward Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-17 Catherine J. Y. Tsai, Jacelyn M. S. Loh, Kohtaro Fujihashi, Hiroshi Kiyono
The unique mucosal immune system allows the generation of robust protective immune responses at the front line of pathogen encounters. The needle-free delivery route and cold chain-free logistic re...
-
Understanding immunity to influenza: implications for future vaccine development Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-12 Ralph A. Tripp
Influenza virus changes its genotype through antigenic drift or shift making it difficult to develop immunity to infection or vaccination. Zoonotic influenza A virus (IAV) strains can become establ...
-
Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand Expert Rev. Vaccines (IF 6.2) Pub Date : 2023-10-12 Karan Thakkar, Julia Spinardi, Moe H. Kyaw, Jingyan Yang, Carlos Fernando Mendoza, Egemen Ozbilgili, Josie Dodd, Ben Yarnoff, Suda Punrin
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 has continuously evolved, requiring the development of adapted vaccines. This study estimated the impact of the introdu...